Navigation Links
Studies look at how genes affect antipsychotic drug response

Researchers at the University of Illinois at Chicago College of Pharmacy are attempting to discover how genes determine how well an antipsychotic medication works in adults and children and the side effects it will cause.

Risperidone, a popular "atypical" antipsychotic medication, is used to treat mental illnesses such as schizophrenia and bipolar disorder.

Jeffrey Bishop, assistant professor of pharmacy practice, is examining the effects of one gene, catechol-o-methyltransferase, on brain activity, cognition and symptom response to the drug.

The study is being done in adults who are experiencing their first episode of schizophrenia who are treated with risperidone for six weeks as part of UIC's First Episode Program.

"Allowing patients with schizophrenia an increased chance at medication response literally could change their lives," Bishop said.

"While we know a great deal about the pharmacology of antipsychotics like risperidone, there is still much to learn about their influence on cognition and brain function, as well as how genetics affect overall medication response," he said.

Bishop says the project will serve as a first step toward a comprehensive pharmacogenetic analysis of metabolic pathways affecting response to the drug. He was presented with an award for new investigators from the American College of Clinical Pharmacy for the project.

The UIC Center for Cognitive Medicine's First Episode Program, directed by Dr. John Sweeney, has been studying patients with first-episode schizophrenia for the past five years.

Bishop is also beginning a second project to study how risperidone may elevate prolactin levels and cause weight gain in children ages 8-18 who suffer from pediatric bipolar disorder. An increase in prolactin (a pituitary hormone that may affect bone development) or weight gain occurs in some but not all of these young patients.

"We are trying to determine if some kids are at a greater risk than others for these problems by analyzing genetic markers," Bishop said.

Bishop said if children are to receive long-term drug therapy, clinicians need to make sure they are appropriately monitored and treated as safely as possible.

"Understanding risperidone pharmacogenetics and whether some individuals are at a higher risk for side effects is an important step in this process," he said.

Risperidone is widely prescribed to treat bipolar disorder in children, accounting for half of all atypical antipsychotic prescriptions in pediatric psychiatry. Adverse drug effects, such as weight gain and the possibility of prolactin elevation, are often dose-limiting and affect medication compliance.


'"/>

Source:University of Illinois at Chicago


Related biology news :

1. Studies reveal methods viruses use to sidestep immune system
2. Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine
3. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
4. Studies on human genome variation provide insight into disease
5. Studies suggest new brain protein may help in treating schizophrenia, insomnia and anxiety
6. Studies find general mechanism of cellular aging
7. Studies yield insight into the numerical brain
8. Studies force new view on biology of flavonoids
9. Newly-discovered class of genes determines ?and restricts ?stem cell fate
10. Inexpensive, mass-produced genes core of synthetic biology advances at UH
11. First atlas of key brain genes could speed research on cancer, neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: